Comparison
Creatine Monohydrate vs MOTS-c
Side-by-side of Creatine Monohydrate and MOTS-c. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Creatine Monohydrate
Creatine monohydrate supplement guide: 3-5 g/day raises phosphocreatine stores, lifts anaerobic output 5-15%, supports lean mass and cognition under sleep loss.
MOTS-c
MOTS-c peptide is a 16-amino-acid mitochondrial-derived peptide. Preclinical signals for insulin sensitivity, exercise capacity, dosage notes.
Effects at a glance
Creatine Monohydrate
- •Increases anaerobic strength and power output by ~5 to 15% across multiple training studies
- •Adds ~1 to 2 kg of lean body mass over 4 to 12 weeks, partly intracellular water and partly true tissue gain
- •Improves 1-rep max on bench and squat by ~5 to 10% versus placebo in resistance-trained adults
- •Cognitive benefit appears mainly under sleep deprivation or high mental load, less so in well-rested individuals
- •Saturation reached in ~28 days at 3 to 5 g/day, or ~5 to 7 days with a 20 g/day loading phase
- •No evidence of renal harm in healthy adults across long-term studies; caution in pre-existing severe renal disease
MOTS-c
- •16-amino-acid peptide encoded in mitochondrial DNA (12S rRNA region); discovered 2015
- •Activates AMPK in skeletal muscle and liver; improves insulin sensitivity in rodent models
- •Circulating endogenous levels decline with age, motivating the longevity-restoration hypothesis
- •CohBar's MOTS-c analog CB4211 discontinued after phase 1b NASH readout did not meet endpoints
- •Anecdotal protocols use 5 to 10 mg subcutaneously 2 to 3 times weekly
- •Not on the WADA Prohibited List as of 2026; future scrutiny likely given exercise-mimetic mechanism
Side-by-side
| Attribute | Creatine Monohydrate | MOTS-c |
|---|---|---|
| Category | supplement | peptide |
| Also known as | creatine | Mitochondrial Open Reading Frame of the Twelve S rRNA-c, MOTSc |
| Half-life (hr) ↗ | 3 | 0.5 |
| Typical dose (mg) ↗ | 5000 | 5 |
| Dosing frequency | daily | 2-3x weekly |
| Routes | oral | subcutaneous |
| Onset (hr) | 168 | 1 |
| Peak (hr) | - | 4 |
| Molecular weight | 149.15 | 1880.18 |
| Molecular formula | C4H9N3O2 | C82H132N22O25S2 |
| Mechanism | Donates a phosphate group to ADP via creatine kinase, regenerating ATP during high-intensity, short-duration efforts. | Mitochondrial-derived peptide that activates AMPK in skeletal muscle and liver, improves insulin sensitivity, and translocates to the nucleus under metabolic stress to modulate nuclear gene expression in retrograde mitochondrial signaling. |
| Legal status | Dietary supplement (most jurisdictions) | Not FDA approved; research-use-only grey market; not currently on WADA Prohibited List |
| WADA status | allowed | unknown |
| DEA / Rx | OTC supplement | Not scheduled (research chemical) |
| Pregnancy | Insufficient data | Insufficient data; not recommended |
| CAS | 57-00-1 | 1627580-64-6 |
| PubChem CID | 586 | 139599184 |
| Wikidata | Q408389 | Q24832108 |
Safety profile
Creatine Monohydrate
Common side effects
- water retention
- mild GI upset at loading doses
- weight gain (2 to 4 lb from intracellular water)
Contraindications
- severe renal impairment
Interactions
- caffeine (high-dose acute): mixed data on ergogenic interference; chronic use appears compatible(minor)
- nephrotoxic drugs (NSAIDs, cyclosporine): theoretical additive renal strain in at-risk patients(moderate)
MOTS-c
Common side effects
- injection-site irritation
- transient fatigue
- headache (anecdotal)
Contraindications
- pregnancy
- lactation
- active malignancy (theoretical)
- severe hypoglycemia risk on concurrent insulin or sulfonylurea
Interactions
- insulin: additive insulin sensitization may increase hypoglycemia risk(moderate)
- metformin: both activate AMPK; theoretical additive metabolic effect, no controlled data(minor)
- sulfonylureas: increased hypoglycemia risk via additive insulin sensitization(moderate)
Which Should You Take?
Creatine Monohydrate comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-A outcome catalogued. MOTS-c is the right call when one of the conditionals below applies.
- → If your priority is strength or hypertrophy, pick Creatine Monohydrate.
- → If your priority is focus or working memory, pick Creatine Monohydrate.
- → If your priority is healthspan extension, pick MOTS-c.
- → If your priority is metabolic health and glucose control, pick MOTS-c.
Edge case: If you want to avoid research-only / gray-market sourcing, Creatine Monohydrate is the more accessible choice.
Default choice: Creatine Monohydrate. Lower friction to source, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for MOTS-c only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Creatine Monohydrate and MOTS-c?
Creatine Monohydrate and MOTS-c differ in category (supplement vs peptide), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Creatine Monohydrate or MOTS-c?
Creatine Monohydrate half-life is 3 hours; MOTS-c half-life is 0.5 hours.
Can you stack Creatine Monohydrate with MOTS-c?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper